CTSO · Cytosorbents Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $10.57M | $10.47M | $13.96M | $13.96M | $11.05M | $11.05M |
| Gross Profit | $26.49M | $25.13M | $22.39M | $20.73M | $32.12M | $29.95M |
| R&D | - | - | $15.73M | $15.12M | $16.38M | $8.81M |
| SG&A | $35.65M | $35.00M | $33.60M | $34.29M | $35.75M | $28.46M |
| Total Operating Expenses | $41.24M | $41.91M | $53.60M | $52.25M | $54.86M | $40.32M |
| D&A | $1.23M | $1.57M | $1.46M | $882.6K | $731.6K | $660.8K |
| Operating Income | ($14.75M) | ($16.79M) | ($31.21M) | ($31.52M) | ($22.74M) | ($10.37M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | ($401.0K) | ($1.69M) | ($813.7K) | ($1.09M) | ($736.0K) | ($1.13M) |
| Net Income | ($8.20M) | ($20.72M) | ($28.51M) | ($32.81M) | ($24.56M) | ($7.84M) |
| EPS - Basic | ($0.13) | ($0.38) | ($0.64) | ($0.75) | ($0.20) | - |
| EPS - Diluted | ($0.13) | ($0.38) | ($0.64) | ($0.75) | ($0.20) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.25M | $3.28M | $14.13M | $22.14M | $52.14M | $71.42M |
| Accounts Receivable | $7.55M | $7.32M | $6.06M | $5.66M | $4.52M | $5.16M |
| Inventory | $5.28M | $2.73M | $3.68M | $3.46M | $4.77M | $2.67M |
| Accounts Payable | $2.87M | $3.34M | $3.80M | $1.66M | $2.81M | $1.84M |
| Current Assets | $20.63M | $21.60M | $25.70M | $33.76M | $64.30M | $82.45M |
| Total Assets | $44.18M | $47.37M | $53.26M | $63.23M | $89.52M | $89.95M |
| Current Liabilities | $9.71M | $9.82M | $14.55M | $9.71M | $13.69M | $10.15M |
| Long-term Debt | $16.67M | $14.00M | $2.54M | $5.00M | - | $0 |
| Total Liabilities | $38.28M | $36.26M | $29.99M | $27.86M | $26.94M | $10.73M |
| Stockholders' Equity | $5.90M | $11.11M | $23.28M | $35.37M | $62.58M | $79.22M |
| Retained Earnings | ($312.21M) | ($304.01M) | ($282.51M) | ($254.00M) | ($221.19M) | ($196.63M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.38M) | ($14.43M) | ($21.66M) | ($28.23M) | ($14.01M) | ($5.61M) |
| Investing Cash Flow | ($415.0K) | ($669.4K) | ($936.2K) | ($6.46M) | ($4.28M) | ($1.68M) |
| Financing Cash Flow | $9.31M | $9.33M | $14.47M | $4.96M | $715.2K | $66.35M |
| CapEx | $164.0K | $284.3K | $538.1K | $6.09M | $3.64M | $708.4K |
| Free Cash Flow | ($12.54M) | ($14.71M) | ($22.19M) | ($34.32M) | ($17.65M) | ($6.32M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 1.53 | 0.71 | 0.78 | 1.05 | 0.72 | 0.81 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -18.6% | -43.7% | -53.5% | -51.9% | -27.4% | -8.7% |
| Return on equity | -138.9% | -186.5% | -122.5% | -92.8% | -39.2% | -9.9% |
| Return on invested capital | -51.6% | -52.8% | -95.5% | -61.7% | - | -10.3% |
| Liquidity | ||||||
| Current ratio | 2.13 | 2.20 | 1.77 | 3.48 | 4.70 | 8.12 |
| Quick ratio | 1.58 | 1.92 | 1.51 | 3.12 | 4.35 | 7.86 |
| Cash ratio | 0.64 | 0.33 | 0.97 | 2.28 | 3.81 | 7.03 |
| Leverage | ||||||
| Debt / Equity | 2.82 | 1.26 | 0.11 | 0.14 | - | 0.00 |
| Debt / Assets | 0.38 | 0.30 | 0.05 | 0.08 | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 7.48 | 4.27 | 2.29 | 1.79 | 1.43 | 1.14 |
| Liabilities / Assets | 0.87 | 0.77 | 0.56 | 0.44 | 0.30 | 0.12 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | 2.00 | 3.83 | 3.79 | 4.03 | 2.32 | 4.13 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 182d | 95d | 96d | 91d | 157d | 88d |
| Days payable outstanding | 99d | 116d | 99d | 43d | 93d | 61d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 6.7x | 4.5x | 2.1x | 1.9x | 2.6x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | 5.4% | 12.2% | 8.0% | -35.4% | 7.2% | 70.3% |
| Operating income growth (YoY) | 12.1% | 46.2% | 1.0% | -38.6% | -119.3% | 45.3% |
| Net income growth (YoY) | 60.4% | 27.3% | 13.1% | -33.6% | -213.4% | 59.3% |
| EPS growth (YoY) | 65.8% | 40.6% | 14.7% | -275.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 14.8% | 33.7% | 35.3% | -94.5% | -179.1% | 63.8% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -46.9% | -52.3% | -34.2% | -43.5% | -21.0% | 2217.6% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Cytosorbents Corp against the 5 most active filers in the same SIC group.